Core Insights - The implementation of the new National Medical Insurance and Commercial Health Insurance Drug Directories in Hunan marks a significant advancement in the multi-tiered medical security system, benefiting 3,253 types of insurance drugs for the insured population [1][8] Group 1: Drug Directory Optimization - The new National Medical Insurance Directory has added 114 high-value drugs while removing 29 low-value drugs, resulting in a total of 3,253 drugs in Hunan's directory. The new additions focus on oncology, chronic diseases, and rare diseases, addressing the accessibility of essential medications [2][9] - To ensure continuity of medication for patients, a 6-month reimbursement transition period is set for removed negotiation drugs, along with an optimized "dual-channel" management mechanism that includes 334 drugs, with 70 new additions [2][9] Group 2: Payment Rules and Mechanisms - Hunan has clarified tiered reimbursement rules, introducing a "self-payment ratio" column in the new directory. Class A drugs and 892 types of traditional Chinese medicine will have zero self-payment, while the self-payment ratio for Class B drugs will be determined by expert review [3][10] - A "special case negotiation" mechanism has been established to support the reimbursement of innovative drugs outside the directory, addressing challenges related to the use of innovative drugs in hospitals and payment limitations for complex cases [3][10] Group 3: Supply Assurance and Accessibility - To ensure timely supply of newly added drugs, Hunan mandates that by the end of December 2025, new drugs must be listed, and by February 2026, medical institutions must ensure availability through procurement channels. Negotiated drugs will not be restricted by "one product, two regulations" [4][11] - The dual-channel supply system allows for both medical institutions and retail pharmacies to provide 334 types of drugs, with a unified electronic prescription center enhancing service convenience [4][11] Group 4: Commercial Insurance Directory - The first version of the Commercial Health Insurance Innovative Drug Directory includes 19 high-value drugs that exceed basic insurance coverage, focusing on advanced treatments such as CAR-T therapy and rare disease medications [5][12] - A "three exclusions" policy has been implemented for the commercial insurance directory, ensuring that these drugs are not included in medical institution drug usage assessments, centralized procurement monitoring, or DRG/DIP payment weight calculations [5][12] Group 5: Price Reduction and Patient Burden Relief - Following the implementation of the dual directories, prices for many nationally negotiated drugs have significantly decreased, directly benefiting patients. For instance, the monthly treatment cost of the newly listed domestic innovative drug Senapali capsules dropped from approximately 17,300 yuan to 9,300 yuan [6][13] - Other drugs, such as Jin Sai growth hormone, have also seen substantial price reductions, with annual treatment costs for a 30 kg child decreasing from about 120,000 yuan to around 30,000 yuan, greatly alleviating family financial burdens [7][13]

Core Points - The new "Chongqing Drug Directory (2025)" has been officially implemented since January 1, 2025, which includes 3,253 drugs in the National Drug Directory and additional local supplements [1] - The updated medical insurance directory has added 114 new drugs with an average price reduction of over 60%, significantly alleviating the financial burden on patients [2] - The new insurance directory for commercial health insurance has included 19 innovative drugs, enhancing treatment options for patients with various conditions [7] Group 1: National Drug Directory Changes - The National Drug Directory (2025) includes 3,253 drugs and 892 traditional Chinese medicine pieces, with Chongqing adding 201 traditional Chinese medicine pieces and 87 medical institution preparations [1] - The average price reduction for newly added drugs is over 60%, benefiting patients with conditions such as cancer and chronic diseases [2] - Specific examples include the price drop of the targeted drug for lung cancer from 12,900 yuan to 4,000 yuan per box [2] Group 2: Chronic Disease Treatment - The new directory has expanded the coverage of 65 drugs, including new indications for existing treatments, such as the inclusion of new targets for non-small cell lung cancer [4] - The price of the drug for Crohn's disease has been reduced from 22,045.02 yuan to 8,130.49 yuan for the intravenous form [3] - The expanded reimbursement range allows for more personalized treatment plans for early-stage breast cancer patients [4] Group 3: Commercial Health Insurance Innovations - The "Commercial Health Insurance Innovative Drug Directory (2025)" includes 19 new drugs, such as targeted therapies for various cancers and CAR-T products for blood cancers [7] - The directory serves as a reference for insurance companies, potentially increasing patient enrollment in commercial health insurance [7] - A new multi-layered medical insurance settlement platform has been launched to streamline the claims process for patients [8]